Elicio Therapeutics Inc. has developed multiple cancer vaccine candidates that concentrate an array of different immunogens in the lymph nodes. ELI-002 is Elicio’s lead clinical program for Kirsten rat sarcoma (KRAS) driven cancers caused by a mutation of the KRAS gene. An “off the shelf” approach designed to stimulate an immune response against the seven KRAS mutations driving 25% of solid tumors, ELI-002 is currently being studied in AMPLIFY-201 – a phase 1 dose escalation study – and AMPLIFY-7P, a phase 1/2 study.
Category
🗞
NewsTranscript
00:00 An estimated 609,820 people will die of cancer in the United States this year, according
00:07 to the National Cancer Institute.
00:09 Promising results from a 12-year-old clinical-stage biotechnology company have experts optimistic
00:13 about the future of treating this deadly disease.
00:16 With its proprietary Amphiphile, or AMP, platform, Eliseo Therapeutics has developed multiple
00:21 cancer vaccine candidates that concentrate an array of different immunogens in the lymph
00:24 nodes.
00:25 In September, Eliseo released new information about the vaccine candidates in its pipeline
00:29 at the 9th AACR Special Conference on Pancreatic Cancer in Boston.
00:33 The positive preliminary relapse-free survival data from the ongoing AMPLIFI 201 study demonstrated
00:38 an 86% reduction in risk of progression or death in patients with large T-cell responses
00:43 induced by ELI0022P, a two-peptide formulation designed to treat cancers driven by G12D and
00:51 G12R mutations in CRAS.
00:53 Despite the AMPLIFI F201 study not including a control arm, the median RFS of over 16 months
00:58 is significantly longer than what's been seen in other studies of similar patient groups.
01:02 Alongside AMPLIFI 201, ELI0027P is currently being studied in AMPLIFI 7P, a Phase 1/2 trial
01:08 in patients with high relapse risk and CRAS-driven solid tumors.
01:13 Designed to provide immune response coverage against seven of the most common CRAS mutations,
01:16 the ELI0027P formulation increases the potential patient population for ELI002 while possibly
01:23 reducing the chance of bypassing resistance mechanisms.
01:26 Moving forward in early 2024, Alisio Therapeutics plans to initiate a randomized Phase 2 trial
01:32 studying ELI0027P as a monotherapy in adjuvant PDAC patients.
01:37 (upbeat music)